{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:22:18Z","timestamp":1789150938992,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015351","name":"Pearl Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017478","name":"Usona Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["00461"],"award-info":[{"award-number":["00461"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cct.2022.106976","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T21:55:26Z","timestamp":1667339726000},"page":"106976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial"],"prefix":"10.1016","volume":"123","author":[{"given":"Kelley C.","family":"O'Donnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Mennenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey T.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha K.","family":"Podrebarac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa A.","family":"Forcehimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Bogenschutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cct.2022.106976_bb0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.cct.2022.106976_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Q J Stud Alcohol"},{"issue":"10","key":"10.1016\/j.cct.2022.106976_bb0015","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2022.106976_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2022.106976_bb0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"J. Nerv. Ment. Dis."},{"issue":"11","key":"10.1016\/j.cct.2022.106976_bb0030","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cct.2022.106976_bb0035","doi-asserted-by":"crossref","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Q J Stud Alcohol"},{"issue":"3","key":"10.1016\/j.cct.2022.106976_bb0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.cct.2022.106976_bb0045","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cct.2022.106976_bb0050","series-title":"Project MATCH Monograph Series","article-title":"Motivational enhancement therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence","volume":"vol. 2","author":"Miller","year":"1992"},{"key":"10.1016\/j.cct.2022.106976_bb0055","series-title":"Manual for Protocol 0004, NIDA Clinical Trials Network","article-title":"A manual for motivational enhancement treatment (MET) to improve treatment engagement and outcome in subjects seeking treatment for substance abuse","author":"Obert","year":"2000"},{"key":"10.1016\/j.cct.2022.106976_bb0060","series-title":"Combined Behavioral Intervention manual: A clinical research guide for therapists treating people with alcohol abuse and dependence (Vol. 1)","year":"2004"},{"issue":"4","key":"10.1016\/j.cct.2022.106976_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0022167816673493","article-title":"Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism","volume":"57","author":"Bogenschutz","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"23","key":"10.1016\/j.cct.2022.106976_bb0070","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/jama.2017.18556","article-title":"Guidelines for the content of statistical analysis plans in clinical trials","volume":"318","author":"Gamble","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cct.2022.106976_bb0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.cct.2022.106976_bb0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.cct.2022.106976_bb0085","series-title":"Contemporary Approaches to Assessing Mediation in Communication research, in the Sage Sourcebook of Advanced Data Analysis Methods for Communication research","first-page":"13","author":"Preacher","year":"2008"},{"key":"10.1016\/j.cct.2022.106976_bb0090","series-title":"Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach","author":"Hayes","year":"2013"},{"issue":"1","key":"10.1016\/j.cct.2022.106976_bb0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpdd.796","article-title":"Exposure-response analysis to assess the concentration-QTc relationship of psilocybin\/psilocin","volume":"10","author":"Dahmane","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1016\/j.cct.2022.106976_bb0100","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2022.106976_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.cct.2022.106976_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage Cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.cct.2022.106976_bb0115","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/0269881118780713","article-title":"High dose psilocybin is associated with positive subjective effects in healthy volunteers","volume":"32","author":"Nicholas","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.cct.2022.106976_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2022.106976_bb0130","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"Int Psychiatry Clin"},{"issue":"12","key":"10.1016\/j.cct.2022.106976_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.cct.2022.106976_bb0140","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.cct.2022.106976_bb0145","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.cct.2022.106976_bb0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.cct.2022.106976_bb0155","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of Oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cct.2022.106976_bb0160","series-title":"Poster Presented at the College on Problems of Drug Dependence Annual Meeting in Montreal, Canada","article-title":"Developing psilocybin as a potential pharmacotherapy: identifying optimal dosing parameters","author":"Garcia-Romeu","year":"2017"},{"issue":"4","key":"10.1016\/j.cct.2022.106976_bb0165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1037\/1064-1297.4.4.421","article-title":"Reinforcing, subjective, and performance effects of lorazepam and diphenhydramine in humans","volume":"4","author":"Mumford","year":"1996","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.cct.2022.106976_bb0170","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0269881109359095","article-title":"Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid","volume":"25","author":"Feltner","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.cct.2022.106976_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1360-0443.2003.00631.x","article-title":"A postmarketing study of relative abuse liability of hypnotic sedative drugs","volume":"99","author":"Jaffe","year":"2004","journal-title":"Addiction"},{"issue":"Suppl. 9","key":"10.1016\/j.cct.2022.106976_bb0180","first-page":"31","article-title":"Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds","volume":"66","author":"Griffiths","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2022.106976_bb0185","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-3565(25)10815-X","article-title":"Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability","volume":"262","author":"Preston","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.cct.2022.106976_bb0190","first-page":"717","article-title":"The effects of Benadryl and Hismanal on mood, physiological measures, antihistamine detection, and subjective symptoms","volume":"64","author":"Rice","year":"1993","journal-title":"Aviat. Space Environ. Med."},{"issue":"8","key":"10.1016\/j.cct.2022.106976_bb0195","first-page":"726","article-title":"The effects of Benadryl and Hismanal on psychomotor performance and perceived performance","volume":"64","author":"Rice","year":"1993","journal-title":"Aviat. Space Environ. Med."},{"issue":"3","key":"10.1016\/j.cct.2022.106976_bb0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hup.2524","article-title":"A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers","volume":"31","author":"Inami","year":"2016","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"10.1016\/j.cct.2022.106976_bb0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.cct.2022.106976_bb0210","series-title":"Symposium: Drug addiction treatment with classic psychedelics. Presented at the 80th annual meeting of the College on Problems of Drug Dependence","article-title":"Psilocybin treatment of cocaine use disorder","author":"Hendricks","year":"2018"},{"issue":"3","key":"10.1016\/j.cct.2022.106976_bb0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr Drug Abuse Rev"},{"issue":"11","key":"10.1016\/j.cct.2022.106976_bb0220","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.cct.2022.106976_bb0225","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion Combined with mindfulness-based Behavioral modification to treat cocaine dependence: A randomized clinical trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2022.106976_bb0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1556\/2054.2019.026","article-title":"Psilocybin for depression: considerations for clinical trial design","volume":"3","author":"O\u2019Donnell","year":"2019","journal-title":"Journal of Psychedelic Studies"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422003020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422003020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:58:46Z","timestamp":1761555526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714422003020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":45,"alternative-id":["S1551714422003020"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2022.106976","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2022.106976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106976"}}